JP2021533152A5 - - Google Patents

Info

Publication number
JP2021533152A5
JP2021533152A5 JP2021506326A JP2021506326A JP2021533152A5 JP 2021533152 A5 JP2021533152 A5 JP 2021533152A5 JP 2021506326 A JP2021506326 A JP 2021506326A JP 2021506326 A JP2021506326 A JP 2021506326A JP 2021533152 A5 JP2021533152 A5 JP 2021533152A5
Authority
JP
Japan
Prior art keywords
pyrimidine
compound
nitrooxy
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533152A (ja
JP7596257B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070597 external-priority patent/WO2020030489A1/en
Publication of JP2021533152A publication Critical patent/JP2021533152A/ja
Publication of JP2021533152A5 publication Critical patent/JP2021533152A5/ja
Priority to JP2024125823A priority Critical patent/JP2024150732A/ja
Application granted granted Critical
Publication of JP7596257B2 publication Critical patent/JP7596257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506326A 2018-08-06 2019-07-31 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬 Active JP7596257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125823A JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18187482.7 2018-08-06
EP18187482 2018-08-06
EP18210147 2018-12-04
EP18210147.7 2018-12-04
PCT/EP2019/070597 WO2020030489A1 (en) 2018-08-06 2019-07-31 Nitric oxide releasing phosphodiesterase type 5 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125823A Division JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬

Publications (3)

Publication Number Publication Date
JP2021533152A JP2021533152A (ja) 2021-12-02
JP2021533152A5 true JP2021533152A5 (enExample) 2022-08-08
JP7596257B2 JP7596257B2 (ja) 2024-12-09

Family

ID=67539493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506326A Active JP7596257B2 (ja) 2018-08-06 2019-07-31 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬
JP2024125823A Pending JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125823A Pending JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬

Country Status (11)

Country Link
US (2) US11980618B2 (enExample)
EP (1) EP3833395A1 (enExample)
JP (2) JP7596257B2 (enExample)
KR (1) KR102836746B1 (enExample)
CN (2) CN112566670B (enExample)
AU (1) AU2019319004B2 (enExample)
BR (1) BR112021001950A2 (enExample)
CA (1) CA3108551A1 (enExample)
MX (2) MX2021001503A (enExample)
TW (1) TWI839375B (enExample)
WO (1) WO2020030489A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969139T3 (es) * 2020-02-05 2024-05-16 Nicox Sa Composiciones para el tratamiento del glaucoma e hipertensión ocular
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技(上海)有限公司 Rock激酶抑制剂的硝基氧衍生物
WO2022022669A1 (en) * 2020-07-30 2022-02-03 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
WO2022090379A1 (en) 2020-11-02 2022-05-05 Nicox S.A. No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration
UY39509A (es) * 2020-11-09 2022-01-31 Ildong Pharmaceutical Co Ltd Compuestos inhibidores de la pde-5 y/o la pde-6 donantes de óxido de nitrógeno, y usos de estos
WO2023005180A1 (en) * 2021-07-30 2023-02-02 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
US20250017928A1 (en) 2021-12-02 2025-01-16 Nicox Sa Ophthalmic pharmaceutical compositions containing a nitric oxide-releasing phosphodiesterase 5 inhibitor and method for the preparation thereof
PL4233867T3 (pl) 2022-02-24 2026-02-09 Nicox Sa Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149521A (ja) 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US4975428A (en) 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
CA2383466C (en) * 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
KR100358083B1 (ko) 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
WO2008075152A1 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension
US7993616B2 (en) 2007-09-19 2011-08-09 C-Quest Technologies LLC Methods and devices for reducing hazardous air pollutants
CA2706082C (en) 2008-02-07 2017-10-03 Nicox S.A. Nitric oxide donor compounds
WO2010096320A2 (en) * 2009-02-18 2010-08-26 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
CN102498088A (zh) 2009-09-15 2012-06-13 帝斯曼知识产权资产管理有限公司 硝基氧基酯及其制备和用途
DK2512479T3 (en) * 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
EP2911656B1 (en) 2012-10-23 2020-12-02 Nicox SA Quinone based nitric oxide donating compounds for ophthalmic use
EP2826491A1 (en) 2013-07-15 2015-01-21 Nicox Science Ireland Ophthalmic compositions containing a nitric oxide donor
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
ES2632808T3 (es) 2014-09-04 2017-09-15 Nicox Science Ireland Compuestos de carnosina donadores de óxido nítrico
CA2968010A1 (en) 2014-11-19 2016-05-26 Nicox S.A. Combinations of prostaglandins and nitric oxide donors
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
US10047047B2 (en) 2015-03-31 2018-08-14 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
KR102862562B1 (ko) 2015-11-16 2025-09-19 토파두르 파마 아게 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도
EP3630769B1 (en) 2017-05-22 2025-07-02 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP7249374B2 (ja) 眼疾患を処置するための組成物、製剤、および方法
AU2016204410B2 (en) Methods for treating vascular leak syndrome
JP2013531063A (ja) 二官能基Rhoキナーゼ阻害化合物、組成物およびその使用
US20100022590A1 (en) Novel compounds
EP2597953A1 (en) Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
CN112566670B (zh) 一氧化氮释放第5型磷酸二酯酶抑制剂
US20120077854A1 (en) Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
KR102792934B1 (ko) 세페타프로스트와 Rho 키나아제 저해제의 조합 의약
WO2019124489A1 (ja) セペタプロストとep2アゴニストとの組み合わせ医薬
EP2528908B1 (en) Therapeutic agents for treatment of ocular hypertension
RU2021104718A (ru) Ингибитор фосфодиэстеразы 5 типа, высвобождающий оксид азота
JP2023547441A5 (enExample)
JP2017525735A5 (enExample)
US8609658B2 (en) N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
JPWO2019124487A1 (ja) オミデネパグの組合せ
US9340534B2 (en) Compounds and methods for treating ocular diseases
WO2026027718A1 (en) Cxcl8 inhibitors for use in the treatment of ocular graft-versus-host disease
AU663595B2 (en) Morpholine and thiomorpholine tachykinin receptor antagonists
US8299068B2 (en) Therapeutically active cyclopentanes
WO2005108396A1 (ja) 角結膜障害治療剤
WO2012165314A1 (ja) アミド化合物